Neo Kuma Ventures
Specialist VC investing in psychedelic therapies, clinics and digital mental health platforms.
- Venture capital
- London
- Type
- Venture capital
- Based in
- London
- Stages
- Pre-seed, Seed, Series A
- Sector focus
- Healthtech, Biotech & Life Sciences
- Cheque size
- 150k-1m average ticket
- Fund size
- Undisclosed
- Founded
- 2020
- Website
- neokuma.co
Neo Kuma Ventures is a London-based venture capital firm specialising in psychedelic healthcare. It backs science-led teams developing psychedelic compounds, clinics and care delivery, and digital therapeutics and platforms for conditions such as depression, anxiety and addiction. The firm targets pre-seed to Series A rounds with average tickets of 150,000 to 1 million, investing globally with a European tilt. Its portfolio has included atai Life Sciences, Beckley Psytech, Small Pharma, Wavepaths, Awakn Life Sciences and Tripp. Neo Kuma also takes part in policy work, partnering with Drug Science and the International Therapeutic Psilocybin Rescheduling Initiative.
Team
- Sean McLintock, Founder LinkedIn
← All investors · Is this your organisation? Request an update
More investors in the directory
The Craftory
Purpose-driven consumer packaged goods brands with category-changing potential
Symvan Capital
EIS and SEIS funds backing B2B SaaS and technology companies from seed to exit
Grafton Capital
Growth capital for European software, AI and tech-enabled businesses
Blackfinch Ventures
EIS and VCT investment in early and growth-stage UK technology businesses
The Conduit Connect
Impact-led UK startups from pre-seed to Series A in climate, health and financial resilience
TrueSight Ventures
Angel-sized cheques at pre-seed and seed, sector-agnostic, into technology companies
Subscribe to Newsletter
Join me on this exciting journey as we explore the boundless world of web design together.